Akari Therapeutics, Plc (AKTX)
| Market Cap | 37.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.93M |
| Shares Out | 32.18M |
| EPS (ttm) | -1.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 1.155 |
| Day's Range | n/a |
| 52-Week Range | 0.850 - 4.400 |
| Beta | 0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 18, 2025 |
About AKTX
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR... [Read more]
Financial Performance
Financial StatementsNews
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent
Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncolog...
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry l...
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced ...
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache...
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala
Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video here BOSTON and LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Akari The...
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have to...
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) ...
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-...
Akari Therapeutics Joins Webull Corporate Connect Service Platform
Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Akari Thera...
Akari Therapeutics Announces Key Leadership Appointments
Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKT...
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16,...
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases,...
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy Pre-IND meeting with FDA completed with pos...
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announ...
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio pr...
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today anno...
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases,...
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammato...
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, ...